Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Hemolytic, Autoimmune 1Anemia, Aplastic 1Anemia 1

Interventions

Epoetin Alfa 3Darbepoetin alfa 3ibrutinib 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1Therapeutics 1Tetradecanoylphorbol Acetate 1Sucrose 1Standard of Care 1Radioimmunodetection 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Molecular Diagnostic Techniques 1Microarray Analysis 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Cyclophosphamide 1Biopsy 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × ibrutinib × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡